Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineGeorgia Deliyannis, Dale I. Godfrey, Mason Littlejohn et al.|EBioMedicine|2023Cited by 17
Human Nasal Epithelium Organoids for Assessing Neutralizing Antibodies to a Protective SARS-CoV-2 Virus-like Particle VaccineJulio Carrera Montoya, Joseph Torresi, Simon Collett et al.|Organoids|2024Cited by 12
mRNA vaccines encoding membrane-anchored RBDs of SARS-CoV-2 mutants induce strong humoral responses and can overcome immune imprintingHareth Al-Wassiti, Colin W. Pouton, Stewart A. Fabb et al.|Molecular Therapy — Methods & Clinical Development|2024Cited by 3
Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59Linda Earnest, Joseph Torresi, Daniel Fernandez‐Ruiz et al.|npj Vaccines|2026Cited by 3
mRNA vaccines encoding membrane-anchored receptor-binding domains of SARS-CoV-2 mutants induce strong humoral responses and can overcome immune imprintingHareth Al-Wassiti, Colin W. Pouton, Stewart A. Fabb et al.|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 2